LUPIA, Antonio
 Distribuzione geografica
Continente #
EU - Europa 14.614
NA - Nord America 183
AS - Asia 45
AF - Africa 1
Totale 14.843
Nazione #
IT - Italia 14.583
US - Stati Uniti d'America 182
SG - Singapore 27
DE - Germania 16
CN - Cina 15
GB - Regno Unito 9
IN - India 2
CA - Canada 1
CI - Costa d'Avorio 1
FI - Finlandia 1
HK - Hong Kong 1
IE - Irlanda 1
NL - Olanda 1
RU - Federazione Russa 1
SK - Slovacchia (Repubblica Slovacca) 1
UA - Ucraina 1
Totale 14.843
Città #
Cagliari 12.909
Uta 1.596
Boardman 84
Ashburn 39
Santa Clara 32
Singapore 17
Naples 11
Sassari 9
Milan 8
Washington 7
Los Angeles 6
Krefeld 5
Islington 3
London 3
Rome 3
Rosignano Marittimo 3
Turin 3
Bad Durrheim 2
Bari 2
Beijing 2
Manfredonia 2
Orotelli 2
Parma 2
Selargius 2
Turate 2
Vaishali Nagar 2
Abidjan 1
Bratislava 1
Council Bluffs 1
Dalian 1
Dublin 1
Enfield 1
Formia 1
Frankfurt am Main 1
Lappeenranta 1
New Bedfont 1
Oliena 1
Prescot 1
Santarcangelo di Romagna 1
Smolensk 1
Toronto 1
Wuhan 1
Zhengzhou 1
Totale 14.773
Nome #
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma 1.053
Development of Cyclic Peptides Targeting the Epidermal Growth Factor Receptor in Mesenchymal Triple-Negative Breast Cancer Subtype 953
Molecular Basis for Non-Covalent, Non-Competitive FAAH Inhibition 778
Is there a role for dual PI3K/mTOR inhibitors for patients affected with lymphoma? 768
Current updates on naturally occurring compounds recognizing sars-cov-2 druggable targets 739
In silico food-drug interaction: A case study of eluxadoline and fatty meal 701
Inside perspective of the synthetic and computational toolbox of JAK inhibitors: Recent updates 680
Multi-targeting bioactive compounds extracted from essential oils as kinase inhibitors 662
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma 630
Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators 624
Ligand-based drug repurposing strategy identified SARS-CoV-2 RNA G-quadruplex binders 605
Computer-based techniques for lead identification and optimization II: Advanced search methods 593
Review about the multi-target profile of resveratrol and its implication in the SGK1 inhibition 589
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 563
Molecular modelling of epitopes recognized by neoplastic B lymphocytes in Chronic Lymphocytic Leukemia 552
Peptide platform as a powerful tool in the fight against covid-19 546
The Mediterranean Diet as source of bioactive compounds with multi-targeting anti-cancer profile 506
Targeting multiple G-quadruplex–forming DNA sequences: Design, biophysical and biological evaluations of indolo-naphthyridine scaffold derivatives 499
A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase VA inhibitors 492
Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes 445
Computer-based techniques for lead identification and optimization i: Basics 426
Identification of Compounds Targeting HuD. Another Brick in the Wall of Neurodegenerative Disease Treatment 306
Mediterranean products as promising source of multi-target agents in the treatment of metabolic syndrome 283
Exploring the DNA2-PNA heterotriplex formation in targeting the Bcl-2 gene promoter: A structural insight by physico-chemical and microsecond-scale MD investigation 201
The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer 184
Molecular and Structural Aspects of Clinically Relevant Mutations of SARS-CoV-2 RNA-Dependent RNA Polymerase in Remdesivir-Treated Patients 169
Privileged Scaffold Hybridization in the Design of Carbonic Anhydrase Inhibitors 98
A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers 94
New Structural Features of Isatin Dihydrothiazole Hybrids for Selective Carbonic Anhydrase Inhibitors 86
Exploring the 1-(4-Nitrophenyl)-3-arylprop-2-en-1-one Scaffold for the Selective Inhibition of Monoamine Oxidase B 86
Design, Synthesis, and Pharmacological Evaluation of Dual FXR-LIFR Modulators for the Treatment of Liver Fibrosis 10
Totale 14.921
Categoria #
all - tutte 19.084
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.084


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20234.313 0 0 0 0 0 13 5 0 31 53 73 4.138
2023/20245.499 1.027 131 156 311 374 756 717 524 221 387 524 371
2024/20255.109 927 1.314 1.389 1.110 369 0 0 0 0 0 0 0
Totale 14.921